-
公开(公告)号：US4640785A
公开(公告)日：1987-02-03
申请号：US685801
申请日：1984-12-24
CPC分类号： G01N33/491 , Y10T436/25375
摘要： This invention is directed to means for inhibiting the apparent shift in the buoyant density of and/or to restore any loss in the buoyant density of the granulocytic white blood cells in a sample of blood, thereby insuring the quality of the separation of lymphocytes and monocytes from granulocytes in a blood sample. The invention comprises contacting a blood sample with a hypertonic fluid containing a low molecular weight organic or inorganic ionic substance and/or with an isotonic or hypertonic fluid containing a high molecular weight organic substance which may contain organic molecules having a lipophilic substituent in their structures and/or with a culture medium for blood cells. An integral part of the invention is an improved blood separation tube utilizing a gel-like substance having a specific gravity between 1.060-1.065 g/cm.sup.3 to significantly enhance the purity of cell separation, while providing acceptable cell yields.
摘要翻译： 本发明涉及用于抑制浮力密度的明显变化和/或恢复血液样品中粒细胞白细胞的浮力密度的任何损失的手段，从而确保淋巴细胞和单核细胞分离的质量 来自血液样品中的粒细胞。 本发明包括使血液样品与含有低分子量有机或无机离子物质的高渗流体和/或含有高分子量有机物质的等渗或高渗流体接触，所述高分子量或高渗流体可以含有在其结构中具有亲脂性取代基的有机分子， /或用于血细胞的培养基。 本发明的一个组成部分是利用比重在1.060-1.065g / cm 3之间的凝胶状物质的改进的血液分离管，以显着提高细胞分离的纯度，同时提供可接受的细胞产量。
-
2.发明授权
公开(公告)号：US4190535A
公开(公告)日：1980-02-26
申请号：US922825
申请日：1978-07-10
CPC分类号： G01N33/491
摘要： This invention relates to a method for isolating platelets, lymphocytes, and monocytes from anticoagulated blood. The method involves centrifuging at high force a sample of uncoagulated blood with a water-insoluble thixotropic gel-like material having a specific gravity between 1.065-1.077 g/cc for a length of time sufficient to cause the gel-like material to form a barrier between the platelets, lymphocytes, monocytes, and plasma fraction of the blood and the heavier blood cells. Thereafter, the plasma is withdrawn and the platelets, lymphocytes, and monocytes removed from above the barrier in a buffer solution. Where desired, the platelets can be separated from the lymphocytes and monocytes utilizing a similar process but wherein the water-insoluble thixotropic gel-like material has a specific gravity of less than about 1.055 g/cc.
摘要翻译： 本发明涉及从抗凝血中分离血小板，淋巴细胞和单核细胞的方法。 该方法包括以非常高的力将具有1.065-1.077g / cc之间的比重的水不溶性触变凝胶状材料的非离子的血液样品离心一段足以使凝胶状材料形成屏障的时间 在血小板，淋巴细胞，单核细胞和血液和较重血细胞的血浆级分之间。 此后，取出血浆，将血小板，淋巴细胞和单核细胞从缓冲溶液中的屏障上方除去。 如果需要，可以使用类似的方法将血小板与淋巴细胞和单核细胞分离，但其中水不溶性触变凝胶状材料的比重小于约1.055g / cc。
-
公开(公告)号：US5053134A
公开(公告)日：1991-10-01
申请号：US466031
申请日：1990-01-17
申请人： Albert A. Luderer , Ward C. Smith
发明人： Albert A. Luderer , Ward C. Smith
CPC分类号： G01N33/491 , B01D21/262 , B01D43/00 , B01D2221/10
摘要： This invention relates to an assembly for centrifugally separating lymphocytes and monocytes from the heavier phases in samples of human blood utilizing a liquid density gradient medium. The particular inventive subject matter concerns the use of novel partition means initially separating the liquid density gradient medium from the sample of blood and designs for such partition means.
摘要翻译： 本发明涉及一种利用液体密度梯度培养基从人体血液样本重离子中离心分离淋巴细胞和单核细胞的装置。 具体的发明主题涉及使用新颖的分隔装置，其最初将液体密度梯度介质从血液样品中分离出来并用于这种分隔装置。
-
公开(公告)号：US4917801A
公开(公告)日：1990-04-17
申请号：US117396
申请日：1987-11-02
申请人： Albert A. Luderer , Ward C. Smith
发明人： Albert A. Luderer , Ward C. Smith
CPC分类号： G01N33/491 , B01D21/262 , B01D43/00 , B01D2221/10
摘要： This invention relates to an assembly for centrifugally separating lymphocytes and monocytes from the heavier phases in samples of human blood utilizing a liquid density gradient medium. The particular inventive subject matter concerns the use of novel partition means initially separating the liquid density gradient medium from the sample of blood and designs for such partition means.
摘要翻译： 本发明涉及一种利用液体密度梯度培养基从人体血液样本重离子中离心分离淋巴细胞和单核细胞的装置。 具体的发明主题涉及使用新颖的分隔装置，其最初将液体密度梯度介质从血液样品中分离出来并用于这种分隔装置。
-
公开(公告)号：US4574782A
公开(公告)日：1986-03-11
申请号：US553376
申请日：1983-11-21
CPC分类号： A61N1/406
摘要： This invention is directed to a method for reducing the mass of a tumor in animal tissue utilizing localized, magnetically-coupled, RF-induced hyperthermia. The method involves the implanting of a material in and/or closely adjacent to the tumor which is non-toxic to, and preferably inert to and compatible with, normal tissue and which has encapsulated therewithin ferromagnetic particles of such size, amount, composition, and ferromagnetism to develop a heating value of up to about one watt/gram, through essentially only hysteresis heating, under an applied field of about 20 but less than 200 oersteds at a frequency greater than 10 kilohertz and ranging up to about 600 kilohertz, or under an applied field of at least about 2000 oersteds and a frequency below about 40 hertz. Such heating value is sufficient to kill the tumor cells but muscle and nerve response of the animal body to the induced emf is minimized.
摘要翻译： 本发明涉及一种利用局部的磁耦合的RF诱导的高热来减少动物组织中肿瘤的质量的方法。 该方法包括在与正常组织无毒且优选为惰性和与之相容的肿瘤中和/或紧密邻近的植入材料，并且在其内封装有这样尺寸，数量，组成和 在大约10千赫，频率高达约600千赫的频率下，在约20但小于200奥斯特的施加电场下，通过基本上只有滞后加热来产生高达约1瓦特/克的发热值，或在下 至少约2000奥斯特的应用场和低于约40赫兹的频率。 这样的加热值足以杀死肿瘤细胞，但是动物身体对诱导的emf的肌肉和神经反应最小化。
-
公开(公告)号：US5698402A
公开(公告)日：1997-12-16
申请号：US393214
申请日：1995-02-23
IPC分类号： G01N33/573 , G01N33/574 , G01N33/68
CPC分类号： G01N33/68 , G01N33/57434
摘要： The present invention relates to a method for diagnosing benign prostatic hyperplasia (BPH) in a male human patient without requiring a biopsy. The total prostate specific antigen (PSA) level in the blood or serum of the patient is measured. If the patient has a total PSA level of between 2.5 ng/ml, (4.0 ng/ml for those 60 years or over), and 10.0 ng/ml, then the free PSA level in the blood or serum of the patient is measured. The proportion of free PSA to total PSA is calculated. If this proportion is equal to or greater than about 25%, then the patient is diagnosed as having BPH.
摘要翻译： 本发明涉及一种用于诊断男性人类患者的良性前列腺增生（BPH）的方法，而不需要活组织检查。 测量患者血液或血清中的总前列腺特异性抗原（PSA）水平。 如果患者的总PSA水平在2.5ng / ml之间（4.0ng / ml，60岁或以上）和10.0ng / ml，则测量患者血液或血清中的游离PSA水平。 计算游离PSA与总PSA的比例。 如果该比例等于或大于约25％，则患者被诊断为具有BPH。
-
7.发明授权Methods for determining suitable patients for prostate surgery incorporating a prostate needle biopsy 失效用于确定合并前列腺手术并入前列腺穿刺活检的患者的方法
公开(公告)号：US5692519A
公开(公告)日：1997-12-02
申请号：US393213
申请日：1995-02-23
IPC分类号： A61B10/00 , A61B10/02 , A61B19/00 , G01N33/574
CPC分类号： A61B10/0241 , G01N33/57434 , A61B2090/395
摘要： The present invention relates to novel methods for determining whether a patient is suitable for prostate surgery, including novel pathology reports and tissue samples. If a patient has a suspicious prostate, a needle biopsy is performed that enables one to map where a tissue anomaly lies with respect to a prostate sextant location, and how far it lies from the prostate capsule. The present method enables a physician to determine if a patient is suitable for prostate surgery, i.e., has at least one malignant tissue anomaly that has not penetrated or is not about to penetrate the prostate capsule. In a preferred form, the present method can enable the physician to determine if a nerve-sparing prostate surgery can be performed on a patient.
摘要翻译： 本发明涉及用于确定患者是否适合于前列腺手术的新方法，包括新的病理学报告和组织样本。 如果患者有可疑的前列腺，则进行针穿刺活检，其能够映射相对于前列腺六分位置的组织异常位置以及前列腺囊具有多远。 本方法使得医师能够确定患者是否适合于前列腺手术，即具有至少一个未穿透或不将穿透前列腺囊的恶性组织异常。 在优选形式中，本方法可使医师能够确定是否可以对患者进行神经保留的前列腺手术。
-
8.发明授权Monoclonal antibodies specific for 330 KD breast tumor antigen and assay using said monoclonal antibodies 失效对330 KD乳腺肿瘤抗原特异性的单克隆抗体和使用所述单克隆抗体的测定
公开(公告)号：US4960716A
公开(公告)日：1990-10-02
申请号：US290852
申请日：1988-12-28
申请人： Michael A. Harvey , Brenda D. Manning , Mary L. Nicholson , Karen L. Travis , Albert A. Luderer
发明人： Michael A. Harvey , Brenda D. Manning , Mary L. Nicholson , Karen L. Travis , Albert A. Luderer
IPC分类号： C07K16/30
CPC分类号： C07K16/3015 , Y10S436/813 , Y10S530/828
摘要： A substantially pure antigen found on normal and benign breast epithelial cell membranes and in breast cancer cells, fused cell hybrids which produce antibodies specific for such antigen, the monoclonal antibodies produced by such fused cell hybrids, a method for detecting the presence of breast cancer in a patient which is based on measuring the concentrations of one or more determinants of such antigen in a patient sample, and a method for either identifying those breast cancer patients whose tumors would respond to estrogen manipulation or determining prognosis based on the degree of differentiation, which method is based on measuring the concentration of an estrogen-modulated determinant of such antigen.
摘要翻译： 在正常和良性乳腺上皮细胞膜和乳腺癌细胞中发现的基本上纯的抗原，产生对这种抗原特异性的抗体的融合细胞杂交体，由这样的融合细胞杂交产生的单克隆抗体，用于检测乳腺癌存在的方法 基于测量患者样品中这样的抗原的一种或多种决定簇的浓度的患者，以及用于鉴定肿瘤将根据分化程度对其进行雌激素操作或确定预后的那些乳腺癌患者的方法，其中 方法是基于测量这种抗原的雌激素调节决定簇的浓度。
-
公开(公告)号：US5710007A
公开(公告)日：1998-01-20
申请号：US536215
申请日：1995-09-29
IPC分类号： G01N33/53 , G01N33/573 , G01N33/574 , G01N33/537 , G01N33/542
CPC分类号： G01N33/57488 , G01N33/57434
摘要： The present invention relates to a method for diagnosing prostatic adenocarcinoma (CAP) in a male human patient without requiring a biopsy. The total prostate specific antigen (PSA) level in the blood or serum of the patient is measured. If the patient has a total PSA level of between 2.5 ng/ml and 20.0 ng/ml, then the free PSA level in the blood or serum of the patient is measured. The proportion of free PSA to total PSA is calculated. If this proportion is less than about 7%, then the patient is diagnosed as having CAP. The present method can also be used on patients that have a total PSA of at least 10.1 ng/ml, but have also had a negative prostate biopsy.
摘要翻译： 本发明涉及一种男性人类患者前列腺腺癌（CAP）诊断方法，无需进行活组织检查。 测量患者血液或血清中的总前列腺特异性抗原（PSA）水平。 如果患者的总PSA水平在2.5ng / ml和20.0ng / ml之间，则测量患者的血液或血清中的游离PSA水平。 计算游离PSA与总PSA的比例。 如果该比例小于约7％，那么患者被诊断为具有CAP。 本方法也可用于总PSA至少为10.1ng / ml，但也具有阴性前列腺活检的患者。
-
公开(公告)号：US4323056A
公开(公告)日：1982-04-06
申请号：US151210
申请日：1980-05-19
IPC分类号： A61B18/12 , A61K9/50 , A61K33/26 , A61K41/00 , A61N1/40 , A61N5/02 , H01F1/37 , H05B6/02 , A61K9/14
CPC分类号： H05B6/106 , A61K41/0052 , A61K9/5094 , A61N1/406 , H01F1/37
摘要： The instant invention is directed to a noninvasive tumor treatment modality which results in a reduction of tumor mass and may lead to complete eradication of a tumor. The inventive method comprises localized magnetically-coupled, RF-induced hyperthermia mediated by a material which is non-toxic to and, preferably, compatible with animal tissue and has incorporated therewithin iron-containing crystals of such size, amount, composition, and magnetic properties to impart a coercive force of at least 200 oersteds to the material, and wherein the RF magnetic field has a frequency not in excess of about 10 kilohertz.
摘要翻译： 本发明涉及一种非侵入性肿瘤治疗方式，其导致肿瘤块的减少并且可导致完全根除肿瘤。 本发明的方法包括由对动物组织无毒且优选与动物组织相容的材料介导的局部磁偶联RF诱导的高热，并且在其中掺入具有这样大小，量，组成和磁性的含铁晶体 以向材料施加至少200奥斯特的矫顽力，并且其中RF磁场的频率不超过约10千赫兹。
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.03 秒)
